June 12, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
GLP-1/amylin receptor agonist lowers HbA1c, weight in type 2 diabetes
NEW ORLEANS — A novel unimolecular GLP-1/amylin receptor agonist conferred reductions in HbA1c and body weight for adults with type 2 diabetes, according to data from a phase 2 trial. Zenagamtide (Novo Nordisk) is under investigation for once-weekly subcutaneous and once-daily oral administration for the treatment of type 2 diabetes and obesity. As Healio previously reported from topline results
TL;DRAI
Non è possibile riassumere questo articolo per Warptech Tech News. L'articolo tratta endocrinologia/farmacologia (trial clinico di zenagamtide per type 2 diabetes) — non rientra nella topica della testata (AI, Tech, Startup, Business, Infrastructure, Cloud, etc.). Non c'è alcuna implicazione di mercato tech o di stack decisionale per manager IT/CTO. Hai l'articolo corretto da riassumere? 👀
920 words~4 min read
